此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估考比司他增强型维奈托克与阿扎胞苷联合治疗新诊断 AML 成人患者的试验 (HO171)

一项单臂 II 期试验,旨在评估考比司他增强型维奈托克与阿扎胞苷 (sc) 联合治疗不被视为强化治疗方案候选者的新诊断急性髓性白血病 (AML) 成年患者

The treatment of older unfit patients with acute myeloid leukemia (AML) is challenging. The hypomethylating agents (HMA) azacitidine and decitabine have relatively mild side effects and have proven to be feasible for the treatment of older patients and patients with co-morbidities. Currently, venetoclax added to an HMA agent is the new standard of treatment. Since this new standard comes with a substantial societal financial burden, there is a rational to optimize the venetoclax dosing schedule. The CYP3A4 inhibitor cobicistat (COBI) can be used to increase venetoclax exposure, thereby allowing to reduce the dose of venetoclax and thus costs substantially.

研究概览

研究类型

介入性

注册 (估计的)

142

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Gerwin Huls, prof
  • 电话号码:+3150 361 2354
  • 邮箱:g.huls@umcg.nl

学习地点

      • 's-Hertogenbosch、荷兰
        • 招聘中
        • NL-Den Bosch-JBZ
        • 接触:
          • A.H.E. Herbers, Dr.
      • Amersfoort、荷兰
        • 招聘中
        • NL-Amersfoort-MEANDERMC
        • 接触:
          • M.F. Corsten, Dr.
      • Amsterdam、荷兰
        • 招聘中
        • NL-Amsterdam-OLVG
        • 接触:
          • H. Mooij, Dr.
      • Amsterdam、荷兰
        • 招聘中
        • NL-Amsterdam-AUMC
        • 接触:
          • C. Alhan, Dr.
      • Arnhem、荷兰
        • 招聘中
        • NL-Arnhem-RIJNSTATE
        • 接触:
          • M.L.H. Cuijpers, Dr.
      • Breda、荷兰
        • 招聘中
        • NL-Breda-AMPHIA
        • 接触:
          • R.B. Fiets, Dr.
      • Dordrecht、荷兰
        • 招聘中
        • NL-Dordrecht-ASZ
        • 接触:
          • P.E. Westerweel, Dr.
      • Eindhoven、荷兰
        • 招聘中
        • NL-Eindhoven-MAXIMAMC
        • 接触:
          • L.W. Tick, Dr.
      • Eindhoven、荷兰
        • 招聘中
        • NL-Eindhoven-CATHARINA
        • 接触:
          • M.J. Cruijsen, Dr.
      • Enschede、荷兰
        • 招聘中
        • NL-Enschede-MST
        • 接触:
          • T.J.F. Snijders, Dr.
      • Groningen、荷兰
        • 招聘中
        • NL-Groningen-UMCG
        • 接触:
          • G.A. Huls, Prof. dr.
      • Leeuwarden、荷兰
        • 招聘中
        • NL-Leeuwarden-MCL
        • 接触:
          • B. Franken, Dr.
      • Leiden、荷兰
        • 招聘中
        • NL-Leiden-LUMC
        • 接触:
          • P.A. von dem Borne, Dr.
      • Maastricht、荷兰
        • 招聘中
        • NL-Maastricht-MUMC
        • 接触:
          • C.H.M.J. van Elssen, Dr.
      • Nieuwegein、荷兰
        • 招聘中
        • NL-Nieuwegein-ANTONIUS
        • 接触:
          • O. de Weerdt, Dr.
      • Nijmegen、荷兰
        • 招聘中
        • NL-Nijmegen-RADBOUDUMC
        • 接触:
          • N.A. de Jonge, Dr.
      • Nijmegen、荷兰
        • 招聘中
        • NL-Nijmegen-CWZ
        • 接触:
          • S. de Jonge, Dr.
      • The Hague、荷兰
        • 招聘中
        • NL-Den Haag-HAGA
        • 接触:
          • D. van Lammeren, Dr.
      • Zwolle、荷兰
        • 招聘中
        • NL-Zwolle-ISALA
        • 接触:
          • T.T. de Waal, Dr.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

In order to be eligible to participate in this study, a patient must meet all of the following criteria:

  • Patients with: a diagnosis of AML and related precursor neoplasms according to ICC-2022 classification (excluding acute promyelocytic leukaemia) (appendix A). Patients may have had previous treatment with erythropoiesis stimulating agents (ESA) for an antecedent phase of MDS. ESAs must be stopped at least two weeks before registration.

  • Patients 18 years and older who are considered not fit for intensive chemotherapy or who decline the option of intensive chemotherapy.

  • WHO performance status 0, 1 or 2 (appendix E).

  • Leukocytes < 30 x109/L

  • Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values:

    • Adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.
    • Serum bilirubin ≤ 3 x upper limit of normal (ULN), unless considered AML-related or due to Gilbert's syndrome.
    • Alanine transaminase (ALT) ≤ 3 x ULN, unless considered AML-related.
  • Male subjects who are sexually active, must agree, from Study Day 1 until at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug.

  • Female subjects must be either postmenopausal defined as: Age >55 years with no menses for ≥12 months, without an alternative medical cause. OR willing and able to use adequate contraception during and until 180 days after the last protocol treatment.

  • Written informed consent.

  • Patient is capable of giving informed consent.

  • Patient agrees not to participate in another interventional study while on treatment without approval of the (co-) Principal Investigator.

Exclusion Criteria:

A patient who meets any of the following criteria cannot be included in this study:

  • Acute promyelocytic leukemia.

  • Myelodysplastic syndrome (MDS).

  • Patients previously treated for AML or MDS (any anti-leukemic therapy including investigational agents; excluding: 1) erythropoiesis stimulating agents (ESAs); 2) hydroxyurea ((previous treatment with hydroxyurea is allowed for the control of peripheral leukemic blasts in patients with leukocytosis).

  • Diagnosis of any previous or concomitant malignancy is an exclusion criterion:

    • except when the patient successfully completed treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 24 months prior to registration;
    • except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix.
  • Blast crisis of chronic myeloid leukemia.

  • Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.).

  • Cardiac dysfunction as defined by:

    • Myocardial infarction within the last 3 months of study entry, or
    • Reduced left ventricular function with an ejection fraction < 40% as measured by MUGA scan or echocardiogram, or
    • Unstable angina or New York Heart Association (NYHA) grade IV congestive heart failure (see Appendix G), or
    • Unstable cardiac arrhythmias.
  • History of stroke or intracranial haemorrhage within 6 months prior to registration.

  • Symptomatic central nervous system (CNS) leukemia (NO routinely lumbar puncture required to investigate CNS involvement).

  • History of non-compliance to medical regimens or considered unreliable with respect to compliance.

  • Senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.

  • Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than hydroxyurea.

  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

  • Unreplaceable use of strong inhibitors or inducers of CYP3A or CYP3A/p-GP substrates with a narrow therapeutic window (e.g. cobicistat or ritonavir for HIV treatment). Please check with Appendix I.

  • Intolerability, contra-indication or allergy to one of the study drugs.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:single arm arm extension phase

prior to the extention phase, there is a run-in phase with (n= 20 patients of 142 total) with the same study scheme, except that cobicistat is added from cycle 2 onwards to the treatment instead of during cycle 1

during run-in and extention phase: from Cycle 1 until relapse

during run-in and extention phase: from Cycle 1 until relapse

during run-in phase: from cycle 2 until relapse

during extension phase: from cycle 1 until relapse

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Pharmacokinetic equivalence of cobicistat boosted venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).
大体时间:6-8 months

run-in phase

6-8 months
Overall survival (OS).
大体时间:48 months

extension phase

48 months

次要结果测量

结果测量
措施说明
大体时间
Venetoclax and cobicistat CL, Cmax, Tmax, Cmin and AUC0-24.
大体时间:6-8 months

run-in phase

6-8 months
Complete remission (CR) rate defined as CR as best response during or at completion of the treatment, as determined by the Investigator, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
大体时间:48 months

extension phase

48 months
CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
大体时间:48 months

extension phase

48 months
CR and CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
大体时间:48 months

extension phase

48 months
CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
大体时间:48 months

extension phase

48 months
CR and CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
大体时间:48 months

extension phase

48 months
CR or CR/CRi or CR/CRh without minimal residual disease (flow and or molecular) (CRMRD- or CR/CRiMRD- or CR/CRhMRD-).
大体时间:48 months

extension phase

48 months
Morphologic leukemia-free state (MLFS) rate, based on ELN2022 recommendations.
大体时间:48 months

extension phase

48 months
Event free survival (EFS).
大体时间:48 months

extension phase

48 months
Relapse-free survival (RFS).
大体时间:48 months

extension phase

48 months
Incidence and severity of adverse events according to CTCAE version 5.0.
大体时间:48 months

extension phase

48 months
Early (30-day and 60-day) mortality (in general, non-leukemic).
大体时间:48 months

extension phase

48 months
Time to next cycle, defined as the time from the start of the cycle until the start of the next cycle.
大体时间:48 months

extension phase

48 months
OS of AZA/VEN/COBI treated patients in comparison with a real-world data cohort treated during the same time period and monitored by the Dutch Cancer registry.
大体时间:48 months

extension phase

48 months
Prognostic/predictive impact of disease-associated genetic changes at diagnosis.
大体时间:48 months

extension phase

48 months
Relapse-associated genetic changes (determined at relapse). The average relative dose intensity will be computed and given by categories. The same will be done for treatment deviation.
大体时间:48 months

extension phase

48 months
Clonal evolution during treatment.
大体时间:48 months

extension phase

48 months
Exposure-response and exposure-toxicity relation of venetoclax in patients with AML.
大体时间:48 months

extension phase

48 months
Cost-savings on venetoclax drug costs.
大体时间:48 months

extension phase

48 months
Adherence to venetoclax and cobicistat.
大体时间:48 months

extension phase

48 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年1月17日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2023年7月4日

首先提交符合 QC 标准的

2023年8月23日

首次发布 (实际的)

2023年8月28日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月18日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅